AbbVie (ABBV) Quality Dividend Play
about 1 month ago
Mark Rousen
"stock number one, which is going to be AVY, stock ticker ABBV. And if you've been subscribed to my newsletter, the Stock Investors Edge, then you know this has been one of my longest held positions in my portfolio. After all, the company spun off from Abbott Labs back in 2013. And since that spin-off, all the stock has done is climb 550%, now making it one of the largest pharmaceutical companies within the S&P 500. Analysts right now rate the stock a moderate buy with an average price target of $252 per share, implying more than 10% upside from current levels to go along with that 3.1% dividend yield."
The speaker highlights AbbVie (ticker ABBV) as a long-term, high-quality dividend stock with stable cash flow and a history of growth, now trading at an attractive level with an analyst moderate buy rating and a 12‐month price target of 252.
Scores
Alpha Potential
8.0/10
Novelty
6.0/10
Credibility
8.0/10
Timeliness
7.0/10
Overall
7.6/10
Sentiment
Bullish
Conviction
High
Tier
Trade Call
Related Stocks
Episode Information
Episode:
5 Quality Stocks to BUY Now
Source:
Mark Roussin, CPA
Published:
December 16, 2025
Idea Type:
Stock Idea